Panacea Biotec reports widening losses as auditors flag stability
The company reported a standalone net loss of ₹2,988 lakh for FY26, double the prior year's loss, prompting an auditor qualification.
— 1 earlier story on Panacea Biotec Ltd. →What's new
- Standalone net loss widened to ₹2,988 lakh in FY26 from ₹1,523 lakh in FY25.
- Auditors issued a going-concern qualification citing negative retained earnings.
- The board declined a dividend for FY26 and appointed a new independent director.
Why this matters
A going-concern qualification is a stark warning that the auditor sees material uncertainty about the company's ability to survive. With losses nearly doubling year-over-year, the omission of a dividend is a symptom of a balance sheet under severe stress.
What we're watching
- The next set of quarterly cash flow disclosures.
- Potential capital raising initiatives to address the negative retained earnings.
- How the new independent director addresses the auditor's qualification.
The full read
Panacea Biotec is in a deepening hole. The firm reported a standalone net loss of ₹2,988 lakh for FY26, a sharp increase from the ₹1,523 lakh lost in FY25. The financial strain is acute enough that auditors have issued a going-concern qualification, pointing directly to the company's negative retained earnings as the source of their doubt. The board responded by skipping the dividend entirely. While the company did manage to appoint a new independent director, that is a minor administrative move against the backdrop of an auditor questioning the business's long-term viability. The open question is how the firm plans to bridge the gap left by these recurring losses. Without a clear path to liquidity, the going-concern note remains the most important part of this report.
Questions answered
- How did the loss compare to the previous year?
- Panacea Biotec reported a standalone net loss of ₹2,988 lakh for FY26, which is higher than the ₹1,523 lakh loss reported for FY25.
- Why did the auditor include a going-concern qualification?
- The auditor noted significant negative retained earnings, which prompted a formal qualification regarding the company's ability to continue as a going concern.
- Will shareholders receive a dividend for FY26?
- No. The board passed over the dividend for the current year due to the company's ongoing losses.
- Were there any leadership changes?
- Yes, the board appointed a new independent director during the meeting.
Story so far
All notes on PANACEABIO →- 31 May 2026 · 1:11 AM IST Panacea Biotec reports widening losses as auditors flag stability
- today Panacea Biotec joins EU consortium to test dengue vaccine in Africa